Late Breaking-Disease-modifying therapy
November 2, 2021
Dimethyl Fumarate Is Associated with Lower Rates of Infection and Lower Infection-Related Healthcare Costs When Compared with Ocrelizumab
Background: Infections in people with multiple sclerosis (PwMS) may have a detrimental effect on disease progression, risk of...
Late Breaking-Disease-modifying therapy
November 2, 2021
US Real World Experience Switching from Infusion and S1P Therapies to Cladribine Tablets: A Single Center Study
Background: Multiple sclerosis (MS) is a chronic neurological disorder and a major cause of disability in young adults. Cladribine tablets...
Late Breaking-Disease-modifying therapy
November 2, 2021
Early Experience with Cladribine Tablets in an Aging Patient Population
Background: Cladribine, a deoxyadenosine analogue prodrug that preferentially depletes lymphocytes, may disrupt the central immune cascade...
Late Breaking-Disease-modifying therapy
November 2, 2021
Humoral and T-Cell Responses to Sars-Cov-2 Vaccination in Multiple Sclerosis Patients Treated with Ocrelizumab
Background: The COVID-19 epidemic raises important questions about the efficacy of vaccines for people treated with ocrelizumab (OCR), an...
Late Breaking-Disease-modifying therapy
November 2, 2021
Variables Affecting Disease Modifying Therapy Adherence and Impact of Adherence on Multiple Sclerosis Patients (Egyptian experience)
Background: Multiple sclerosis (MS) is a chronic immune-mediated neurological disease affecting mainly young adults. MS patients are more...
Late Breaking-Disease-modifying therapy
November 2, 2021
B-Cell Depleters Attenuate the Humoral Response to Sars-Cov-2 Vaccines in Multiple Sclerosis Patients: A Case-Control Study
Background: B-cell depleting agents are FDA approved for the treatment of RRMS (ocrelizumab (OCR) and ofatumumab (OFA)) and PPMS...
Late Breaking-Disease-modifying therapy
November 2, 2021
Primary Results of NOVA: A Randomized Controlled Study of the Efficacy of 6 Week Dosing of Natalizumab Versus Continued 4-Week Treatment
Background: Natalizumab 4-week dosing (Q4W) with 300 mg is approved for treatment of relapsing-remitting multiple sclerosis. Dosing...
Late Breaking-Disease-modifying therapy
November 2, 2021
Sustained B-Cell Depletion By Inebilizumab Is Associated with Decreased Disease Activity in Aquaporin-4 Seropositive Neuromyelitis Optica Spectrum Disorder
Background: Inebilizumab is a humanized, affinity-optimized, anti-CD19 monoclonal antibody approved in Japan, South Korea and the USA to...
Late Breaking-Disease-modifying therapy
November 2, 2021
The Humoral Response to Sars-COV-2 Vaccines in MS Patients: Impact of Dmt, Lymphocyte Count, Immunoglobulins, and Vaccine Type
Background: Certain DMTs may negatively impact the humoral response to SARS-COV-2 vaccines. However, many MS-related clinical, demographic,...
Late Breaking-Disease-modifying therapy
November 2, 2021
Interim Results of Open-Label Multicenter Phase 4 Study Assessing Immune Response to Influenza Vaccine in Patients with Relapsing Multiple Sclerosis Treated with Ofatumumab
Background: Vaccinations comprise an important component of MS management. Data are needed regarding whether ofatumumab (OMB) impacts...